These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 7857774
21. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Matsuda M, Sakashita M, Mizuki Y, Yamaguchi T, Fujii T, Sekine Y. Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872 [Abstract] [Full Text] [Related]
22. Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives. Fonquerna S, Miralpeix M, Pagès L, Puig C, Cardús A, Antón F, Cárdenas A, Vilella D, Aparici M, Calaf E, Prieto J, Gras J, Huerta JM, Warrellow G, Beleta J, Ryder H. J Med Chem; 2004 Dec 02; 47(25):6326-37. PubMed ID: 15566302 [Abstract] [Full Text] [Related]
29. Conformationally restricted analogs of histamine H1 receptor antagonists: trans and cis-1-benzyl-3-dimethylamino-6-phenylpiperidine. Ahmed AE, Hanna PE, Grund VR. J Med Chem; 1976 Jan 07; 19(1):117-22. PubMed ID: 1535 [Abstract] [Full Text] [Related]
33. Novel imidazole derivatives with subtype-selective antimuscarinic activity (2). Miyachi H, Kiyota H, Segawa M. Bioorg Med Chem Lett; 1998 Aug 18; 8(16):2163-8. PubMed ID: 9873506 [Abstract] [Full Text] [Related]
34. Design and synthesis of novel 3-(4-chlorophenyl)-2-(3-substituted propyl thio) quinazolin-4-(3H)-ones as a new class of H1-antihistaminic agents. Alagarsamy V, Parthiban P. Arzneimittelforschung; 2012 Sep 18; 62(9):433-8. PubMed ID: 22855299 [Abstract] [Full Text] [Related]
35. Duration of the antihistaminic effect after discontinuation of ebastine. Frossard N, Vital-Durand D, Mounedji N, Valleteau A. Allergy; 2001 Jun 18; 56(6):553-7. PubMed ID: 11421903 [Abstract] [Full Text] [Related]
36. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency. Reidemeister S, Stark H, Ligneau X, Ganellin CR, Schwartz JC, Schunack W. Pharmazie; 2000 Feb 18; 55(2):83-6. PubMed ID: 10723763 [Abstract] [Full Text] [Related]
37. Synthesis and pharmacological investigation of novel 4-(3-ethylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a] quinazolin-5-ones as a new class of H1-antihistaminic agents. Alagarsamy V, Kavitha K, Rupeshkumar M, Solomon VR, Kumar J, Kumar DS, Sharma HK. Acta Pharm; 2009 Mar 18; 59(1):97-106. PubMed ID: 19304562 [Abstract] [Full Text] [Related]
38. In vivo evidence for a lack of central effect of ebastine, an antihistaminic agent, in rats: a microdialysis study. Fujisaki Y, Itoh Y, Oishi R. Jpn J Pharmacol; 2002 Dec 18; 90(4):353-6. PubMed ID: 12501012 [Abstract] [Full Text] [Related]
39. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Roumestan C, Henriquet C, Gougat C, Michel A, Bichon F, Portet K, Jaffuel D, Mathieu M. Clin Exp Allergy; 2008 Jun 18; 38(6):947-56. PubMed ID: 18498541 [Abstract] [Full Text] [Related]